AFP-464
Two Phase I studies with AFP-464 are currently enrolling in the United States, sponsored by the National Cancer Institute, at the Mayo Clinic, University of Maryland, and Wayne State University. These studies evaluate AFP-464 in patients with Advanced Solid Tumors. For more information on these trials, please use the link below:
ClinicalTrials.gov:
A Phase I study with AFP-464 is currently enrolling in Europe. This study evaluates AFP-464 in patients with Advanced Solid Tumors. The trials is expected to enroll up to 35 patients across two research centers in Europe, with Dr. Ahmad Awada at the Jules Bordet Institute, Brussels, Belgium and Dr. Jean Charles Soria at the Institut Gustave-Roussy Villejuif, France.
Following completion of these trials, Phase II studies of AFP-464 will commence.
GGTI-2418
A Phase I study of GGTI-2418 is currently enrolling in the United States. For more information, please contact Tigris Pharmaceuticals at info@tigrispharma.com
GFB-204
Tigris Pharmaceuticals in currently completing preclinical IND enabling studies and is planning to initiate Phase I studies to evaluate GFB-204 as a potential cancer therapeutic in patients with a variety of solid tumors upon IND acceptance.
